Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ O.OPIQ=?:w
"`WcE/(
£¨ÃâÒßѧרҵºÍרҵ»ù´¡£© LEu_RU?
dZ]['y%
Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© Y'n+,g
y$-;6zk\]
1.Co-stimulators (or co-stimulating molecules) Z]VmTB
NW$_w
2.NK-kB VSf<(udGr
|t <Uh,Bt
3.Immunoglobulin superfamily -l)u`f^n|
xhq-$"B
4.antigen-presenting cell (APC) |/!3 N
YC,)t71l{
5.death domain Z@i"/~B|4\
:U>[*zE4&
6.CCR and CXCR <d`ksZ+
9|('*
7.Lectin (or mitogen) x~;1CB
S8_>Lw
8.Clusters of differentiation, CD) ?^f=7e8]
d<,'9/a>
9.B7 family 6$.I>8n
%
]U'
10.Cytotoxic T lymphocyte, CTL) } ={TVs^
o$Jop"To
11.IL-15 and IL-15 receptor (IL-15R) WciL
zx/
|O!
G[|/3
12.MHC restriction _{k-&I
}HLs.k4-;
13.Affinity-chromatography <meQ
m ?)k&{I
14.Cyctosprin A, CsA O_S%PX
kMJA#{<
15.Antibody-dependent cell-mediated cytotoxicity, ADCC) 7A=*3
aS
$ J `
¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© 4DTT/ER'qA
z&Kh$ $)[
1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 Z!81\5
#
9@K
2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØÏµ¡£ 7]}2`^9
n@PXC8}
3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹ÔµÄÌØµã¡£ wV{jJyRl
@?/> $
Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£© ~:xR0dqx
O,_k.EH
ÃâÒßѧרҵ£º t}X+P`Ovq
^U.t5jj
1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£ 9cJ1J7y
n5z";:
p
Ïû»¯ÄÚ¿Æ£º ;/R \!E
e9p!Caf~I-
2.Ö×Áö¿¹Ô·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ {+CBThC
DPM4v7 S
ѪҺ²¡Ñ§×¨Òµ£º sD{d8s[(
QTmMj@R&(
3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎÎªÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔÒò£¨Ìõ¼þ£©ÊÇʲô£¿